Results regarding the frequency of CDKN2A promoter methylation are inconsistent in prostate tumors, ranging from 3% to 77%; other studies have investigated the role of hypermethylated CDKN2A in the carcinogenesis and progression of PCa [45, 47, 79-85]. Here, CDKN2A is linked to prostate neoplasm.